Allergan Rebounds from Pfizer Breakup with Alzheimer’s Deal

Apr 07, 2016

Wall Street Journal

Hours after its $160 billion Pfizer deal fell apart, Allergan completed a licensing deal with U.K.-based Heptares Therapeutics.

The deal, worth a potential $3.3 billion, gives Allergan global rights to Heptares' Alzheimer’s and neurological disorders portfolio.

Allergan will pay $125 million up front to Heptares (owned by Japan’s Sosei Group Corp.) plus $665 million in milestone payments for the successful completion of clinical trials. An additional $2.5 billion in milestones, plus royalties, depends on commercial success of the portfolio. Allergan has also agreed to invest $50 million in a joint R&D program to advance several drugs to mid-stage human testing.

In regards to the dead Pfizer deal, Pfizer CEO Ian Read released a brief press release, in which he confirmed, "We maintain the financial strength and flexibility to pursue attractive business development and other shareholder friendly capital allocation opportunities.”

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments